Stock HOOK HOOKIPA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Delayed Nasdaq
Other stock markets
 10:30:36 2024-04-18 am EDT 		5-day change 1st Jan Change
0.7732 USD +1.40% Intraday chart for HOOKIPA Pharma Inc. -3.97% -4.54%
Apr. 10 HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200 CI
Mar. 22 HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on HOOKIPA Pharma Inc.

Price target over the last 5 years

History of analyst recommendation changes

8d2c18caa483d45fa3d69cf.NjIRsqATjMqepjMjR83xCHYvi8IpHAYvnYE0QnYmzeE.bGV45vRW4_Px1GwWAae3STd36q8Ea1Na6ddkNyVCrLJHVFeD7lLm8-3Feg~5741d314cd87c10914ec0dc354ddef64

Analyst Recommendations on HOOKIPA Pharma Inc.

RBC Cuts Price Target on HOOKIPA Pharma to $5 From $6 Amid Restructuring Plan, Termination of Roche Partnership on KRAS; Outperform, Speculative Risk Kept MT
HOOKIPA Pharma Says Head, Neck Cancer Phase 2 Study of Therapy Combination Showed 42% Objective Response Rate MT
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $6.50 From $8, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $2.25 From $2, Maintains Equal-Weight Rating MT
Truist Securities Adjusts HOOKIPA Pharma Price Target to $4 From $11, Maintains Buy Rating MT
RBC Trims Price Target on HOOKIPA Pharma to $7 From $8, Affirms Outperform Rating MT
Truist Securities Lowers HOOKIPA Pharma's Price Target to $11 From $16, Maintains Buy Rating MT
SVB Securities Adjusts HOOKIPA Pharma's Price Target to $3 From $4, Keeps Outperform Rating MT
Kempen Upgrades HOOKIPA Pharma to Buy From Neutral, Lifts Price Target to $3 From $2.60 MT
RBC Cuts Price Target on HOOKIPA Pharma to $9 From $11, Maintains Outperform Rating, Speculative Risk Qualifier MT
HC Wainwright Adjusts HOOKIPA Pharma Price Target to $8 From $15, Maintains Buy Rating MT
SVB Leerink Adjusts HOOKIPA Pharma's Price Target to $4 from $3, Maintains Outperform Rating MT
Kempen Downgrades HOOKIPA Pharma to Neutral From Buy, Adjusts Price Target to $2.60 From $24 MT
Morgan Stanley Downgrades HOOKIPA Pharma to Equal-Weight From Overweight; Price Target is $6 MT
HC Wainwright Adjusts Price Target on Hookipa Pharma to $15 From $21, Keeps Buy Rating MT
SVB Leerink Adjusts HOOKIPA Pharma PT to $10 From $28, Maintains Outperform Rating MT
JMP Securities Adjusts Price Target on HOOKIPA Pharma to $11 From $25, Maintains Market Outperform Rating MT
RBC Cuts PT on HOOKIPA Pharma to $17 From $24, Citing Program Prioritization, Timeline Updates; Outperform-Speculative Risk Rating Kept MT
HOOKIPA PHARMA : Morgan Stanley Adjusts Price Target on HOOKIPA Pharma to $18 From $19, Maintains Overweight Rating MT
HOOKIPA PHARMA : HC Wainwright Adjusts HOOKIPA Pharma's Price Target to $21 from $16, Keeps Buy Rating MT
HOOKIPA PHARMA : Morgan Stanley Initiates Coverage on HOOKIPA Pharma With Overweight Rating, $19 Price Target MT
HOOKIPA PHARMA : RBC Adjusts HOOKIPA Pharma's Price Target to $22 From $18, Maintains Outperform-Speculative Risk Rating MT
HOOKIPA PHARMA : Truist Starts HOOKIPA Pharma at Buy With $21 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.7625 USD
Average target price
4.89 USD
Spread / Average Target
+541.31%
High Price Target
6.45 USD
Spread / Highest target
+745.90%
Low Price Target
4 USD
Spread / Lowest Target
+424.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering HOOKIPA Pharma Inc.

RBC Capital Markets
HC Wainwright
Morgan Stanley
Truist Securities
SVB Securities LLC
Kempen
SVB Leerink
JMP Securities

Ratings for HOOKIPA Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HOOK Stock
  4. Consensus HOOKIPA Pharma Inc.